Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma

Launched by HEPATOPANCREATOBILIARY SURGERY INSTITUTE OF GANSU PROVINCE · Apr 3, 2017

Keywords

ClinConnect Summary

This clinical trial is exploring the effects of using a special type of liquid, called a 37℃ non-ionic contrast agent, during a procedure known as endoscopic retrograde cholangiopancreatography (ERCP) for patients with hilar cholangiocarcinoma, a type of bile duct cancer. The researchers want to see if this temperature-controlled liquid can help reduce complications related to cholangitis, which is an infection of the bile duct that can sometimes occur after the ERCP procedure.

To participate in this trial, individuals must be between 18 and 90 years old and have been diagnosed with specific types of hilar cholangiocarcinoma. They should also have undergone an ERCP for diagnosis or treatment. However, people with certain health issues, such as blood clotting problems, severe infections, or previous surgeries on the digestive system, will not be eligible to join. Participants can expect to be monitored closely during the study, and their health outcomes will be tracked to understand the benefits and risks of using this contrast agent. Overall, this study aims to improve the safety and effectiveness of treatments for patients facing this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Type Ⅰ、Ⅱ、Ⅲ、Ⅳ of Hilar Cholangiocarcinoma;
• • Age: 18\~90 years old;
• • Underwent diagnostic and therapeutic ERCP;
• Exclusion Criteria:
• • Coagulation dysfunction(INR\>1.3) or/and low peripheral blood platelet count （PLT \<50x10\^9/L）;
• • Preoperative acute cholangitis;
• • Preoperative acute pancreatitis;
• • Preoperative hemobilia or hemorrhage of digestive tract;
• • Preoperative liver failure;
• • Combined with Mirizzi syndrome and intrahepatic bile duct stones;
• • Preoperative malignant tumor of biliary system such as carcinoma of head of pancreas, gallbladder carcinoma;
• • Biliary-duodenal fistula confirmed during ERCP;
• • A history of reconstructive surgery for upper digestive tract except Billroth Ⅰand a history of cholangioenterostomy including cholangio-jejunostomy and side to side anastomosis of the bile duct and duodenum;
• • Previous ERCP;
• • Pregnant women